CONFERENCE CALL INFORMATION
Mazor will hold a conference call for the investment community today at 10:00 AM ET, and a webcast will be accessible via the Company’s website. A replay of the call will be available for two weeks following the event.
Date: November 27, 2012
Time: 10:00 AM ET
Audio Webcast:
www.mazorrobotics.com,
click Investors
Live Dial-In (U.S.): 1-866-225-8754
Live
Dial-In (International): 1-480-629-9818
Conference ID: 4578122
Replay Dial-In: 1-800-406-7325
Replay Access Code: 4578122
About Mazor
Mazor Robotics (TASE: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants in the United States and Europe. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, please visit www.mazorrobotics.com.
|
Condensed Interim Consolidated Statements of Income |
|||||||||||||||
|
Nine months ended
September 30, |
Three months ended
September 30, |
Year ended
December 31, |
|||||||||||||
| 2012 | 2011 | 2012 | 2011 | 2011 | |||||||||||
| Unaudited | Audited | ||||||||||||||
| NIS in thousands (except per share data) | |||||||||||||||
| Revenues | 36,644 | 14,306 | 16,239 | 5,984 | 21,302 | ||||||||||
| Cost of sales | 8,360 | *) 4,821 | 3,264 | *) 1,895 | 6,725 | ||||||||||
| Gross profit | 28,284 | 9,485 | 12,975 | 4,089 | 14,577 | ||||||||||
| Selling and marketing expenses | 25,110 | *) 18,456 | 9,393 | *) 6,651 | 25,018 | ||||||||||
| General and administrative expenses | 4,948 | *) 4,732 | 1,532 | *) 1,346 | 5,867 | ||||||||||
| Research and development expenses, net | 7,703 | *) 8,454 | 2,903 | *) 2,859 | 10,959 | ||||||||||
| Operating loss | (9,477 | ) | (22,157 | ) | (853 | ) | (6,767 | ) | (27,267 | ) | |||||
| Finance income | 2,503 | 2,065 | 821 | 1,428 | 2,735 | ||||||||||
| Finance expenses | (3,156 | ) | (2,552 | ) | (1,159 | ) | (1,206 | ) | (3,394 | ) | |||||
| Finance expenses, net | (653 | ) | (487 | ) | (338 | ) | 222 | (659 | ) | ||||||
| Loss before taxes on income | (10,130 | ) | (22,644 | ) | (1,191 | ) | (6,545 | ) | (27,926 | ) | |||||
| Taxes on income | (81 | ) | 50 | (96 | ) | 21 | (242 | ) | |||||||
| Loss for the period | (10,049 | ) | (22,694 | ) | (1,095 | ) | (6,566 | ) | (27,684 | ) | |||||
| Loss per share: | |||||||||||||||
| Basic and diluted loss per share (in NIS) | (0.45 | ) | (1.05 | ) | (0.05 | ) | (0.30 | ) | (1.27 | ) | |||||
